ArticleFrontiers in oncology2026
Multiparametric MRI-based nomogram integrating clinicopathological factors for predicting HER2 expression status in breast cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Human epidermal growth factor receptor 2 (HER2) expression in breast cancer (BC) determines the options for targeted therapy. Multiparametric MRI (mpMRI) has the potential for noninvasive HER2 status prediction but remains underexplored. Objectives: To develop and validate an mpMRI-based nomogram incorporating clinicopathological factors for predicting HER2 status in BC patients. Methods: In this retrospective analysis, 313 BC patients were classified as HER2-overexpression, HER2-low, or HER2-zero on the basis of immunohistochemistry and fluorescence Results: CA125, Ki-67, the minimum apparent diffusion coefficient (ADC-min), and early-phase maximum enhancement (ME) differed significantly among the HER2 subgroups. The nomogram integrating these factors achieved AUCs of 0.762 (95% CI: 0.686-0.838) and 0.738 (95% CI: 0.594-0.882) in differentiating HER2-over/HER2-low from HER2-zero in the training and validation datasets, respectively. Differentiation between the HER2-over and HER2-low subtypes exhibited AUCs of 0.719 and 0.772, respectively. Conclusions: Our nomogram, which combines mpMRI and clinicopathological variables, effectively predicts HER2 expression in BC patients, providing a promising noninvasive clinical tool to guide targeted therapy selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.